Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-06-19

Clinical Trial Update: Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating rasagiline for persistent negative symptoms in schizophrenia; study completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RASAGILINE (rasagiline)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2013-06-19